Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation

M. F. Fitzgerald, D. Spicer, E. Clark, N. Bowyer (Stoke Poges, United Kingdom)

Source: Annual Congress 2001 - New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Session: New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Session type: Poster Discussion
Number: 343
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. F. Fitzgerald, D. Spicer, E. Clark, N. Bowyer (Stoke Poges, United Kingdom). Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation. Eur Respir J 2001; 16: Suppl. 31, 343

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models
Source: Eur Respir J 2001; 18: Suppl. 33, 36s
Year: 2001

A selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in guinea-pig antigen challenge and ferret emesis models
Source: Eur Respir J 2001; 18: Suppl. 33, 36s
Year: 2001

Efficacy of the PDE4 inhibitor, BAY 19-8004, in a smoke-induced model of pulmonary inflammation in the guinea pig
Source: Eur Respir J 2001; 18: Suppl. 33, 36s
Year: 2001

Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004
Source: Eur Respir J 2001; 18: Suppl. 33, 36s
Year: 2001

The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit
Source: Eur Respir J 2001; 18: Suppl. 33, 35s
Year: 2001

The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 107s
Year: 2003

Effect of phosphodiesterase 4 (PDE-4) inhibitor – rolipram with or without co-administration of dexamethasone on experimental asthma - guinea pig model
Source: Eur Respir J 2004; 24: Suppl. 48, 128s
Year: 2004

The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions
Source: Eur Respir J 2001; 18: Suppl. 33, 34s
Year: 2001

Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002

Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 128s
Year: 2004

Roflumilast N-oxide, a PDE4 inhibitor, curbs bleomycin-induced lung fibroblast activation in vitro
Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology
Year: 2011


In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014


Phosphodiesterase 4 inhibition of β2-integrin adhesion caused by leukotriene B4 and TNF-α in human neutrophils
Source: Eur Respir J 2006; 28: 920-928
Year: 2006



Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 303s
Year: 2002

Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 198s
Year: 2001

Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019

Phosphodiesterase 4-5 inhibitor (LASSBio596) per os avoided pulmonary mechanical impairment and inflammation produced by microcystin-LR
Source: Annual Congress 2009 - Experimental approaches in animals and modelling in humans
Year: 2009


Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury
Source: Eur Respir J 2003; 22: 20-27
Year: 2003



The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 34s
Year: 2001

The selective PDE4-inhibitor AWD 12-281 inhibits LPS-induced neutrophilia in domestic pig lung, an animal model of COPD: comparison with steroids
Source: Eur Respir J 2001; 18: Suppl. 33, 160s
Year: 2001